🔥🐔 BizChicken 🐔🔥
Companies Similar to Processa Pharmaceuticals, Inc.
Sign Up Today!
Sign up for BizChicken and discover more about the corporations around you.
Contineum Therapeutics, Inc. Class A Common Stock
PIPE-791
Contineum Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need.
Symbol: CTNM
Recent Price: $14.47
Industry: Biotechnology
CEO: Mr. Carmine N. Stengone MBA, MS
Sector: Healthcare
Employees: 31
Address: 10578 Science Center Drive, San Diego, CA 92121
Phone: (858) 333-5280
Leadership
- Carmine Stengone, President and Chief Executive Officer
- Austin Chen, PhD, Senior Vice President, Head of Research
- Beverly Dixon, Senior Director, Quality Assurance
- Kristina Haeckl, Sr. Vice President, Regulatory Affairs
- Daniel Lorrain, PhD, Chief Scientific Officer
- John Healy, General Counsel & Corporate Secretary
- Jon Seiders, PhD, Vice President, CMC
- Jules Lee, Senior Director, Clinical Operations
- Julie Iwashita, Vice President, Clinical Operations
- Karin Stebbins, Vice President, Toxicology
- Michael Mayberry, Vice President, Finance
- Mike Poon, PhD, Vice President, Biology
- Peter Slover, Chief Financial Officer
- Stephen Huhn, MD, Chief Medical Officer & Senior Vice President, Clinical Development
- Tara Vargas, Senior Director, Project Management
- Thomas O. Schrader, PhD, Senior Director, Chemistry
- Varsha Dourado, Vice President, Business Development
Last updated: 2024-12-31
KalVista Pharmaceuticals, Inc.
KVD001, sebetralstat, KVD824, Factor XIIa
Kal Vista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company focused on discovering, developing, and commercializing small molecule protease inhibitors for diseases with unmet needs, including hereditary angioedema and diabetic macular edema.
About | About | Management | Directors | About | Contact | Careers | Careers | About | About | About | About | About | About | ESG | About | About | Careers | About | About
Symbol: KALV
Recent Price: $8.39
Industry: Biotechnology
CEO: Mr. Benjamin L. Palleiko
Sector: Healthcare
Employees: 150
Address: 55 Cambridge Parkway, Cambridge, MA 02142
Phone: 857 999 0075
Leadership
- Albert Cha, Member of Board of Directors
- William (Bill) Fairey, Member of Board of Directors
- Benjamin L. Palleiko, Chief Executive Officer and Director
- Brian J. G. Pereira, Member of Board of Directors
- Nancy Stuart, Member of Board of Directors
- Pat Treanor, Member of Board of Directors
- Edward W. Unkart, Member of Board of Directors
Last updated: 2024-12-31
Passage Bio, Inc.
PBGM01, PBFT02, PBKR03, PBML04, PBAL05, PBCM06
Passage Bio, Inc. develops transformative therapies for central nervous system diseases using proprietary genetic medicine technologies to deliver functional genes for the treatment of various disorders.
Symbol: PASG
Recent Price: $0.67
Industry: Biotechnology
CEO: Dr. William Chou M.D.
Sector: Healthcare
Employees: 58
Address: One Commerce Square, Philadelphia, PA 19103
Phone: 267 866 0311
Leadership
- William Chou, MD, President and Chief Executive Officer
- Kathleen Borthwick, Chief Financial Officer
- Sue Browne, PhD, Chief Scientific Officer
- Edgar B. (Chip) Cale, General Counsel and Corporate Secretary
- Eden Fucci, SVP Technical Operations
- Stuart Henderson, Chief Business Officer
- Karl Whitney, PhD, SVP Global Regulatory Affairs
- James M. Wilson, MD, PhD, Scientific Advisor
- Maxine Gowen, PhD, Chairwoman
- Athena Countouriotis, MD,
- Derrell D. Porter, MD,
- Dolan Sondhi, PhD,
- Sandip Kapadia,
- Tom Kassberg,
- Saqib Islam,
- Samiah Al-Zaidy, MD, Vice President, Clinical Development
- Andrea Campanile, Vice President, Clinical Operations
Last updated: 2024-12-31
Processa Pharmaceuticals, Inc.
PCS499
Processa Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company that develops drug products for patients with unmet medical needs in the United States. Key products include PCS499 for necrobiosis lipoidica and PCS12852 for gastrointestinal disorders.
Symbol: PCSA
Recent Price: $0.92
Industry: Biotechnology
CEO: Mr. George K. Ng Esq., J.D.
Sector: Healthcare
Employees: 13
Address: 7380 Coca Cola Drive, Hanover, MD 21076
Phone: 443 776 3133
Leadership
- George Ng, Chief Executive Officer
- David Young, Pharm.D., Ph.D., President, Research & Development and Founder
- Sian Bigora, Pharm.D., Chief Development and Regulatory Officer and Founder
- Wendy Guy, Chief Administrative Officer & Founder
- Patrick Lin, Chief Business & Strategy Officer and Founder
- Russell L. Skibsted, Chief Financial Officer
- Justin W. Yorke, Chairman of the Board
- Khoso Baluch, Independent Director
- James R. Neal, Independent Director
- Geraldine Pannu, Independent Director
Last updated: 2024-12-31
Royalty Pharma plc
biopharmaceutical royalties
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry, collaborating with various partners to acquire royalties on marketed and development-stage therapies in multiple therapeutic areas.
Contact | Contact | About | About | News | About | About | News | About | About | About | About
Symbol: RPRX
Recent Price: $25.32
Industry: Biotechnology
CEO: Mr. Pablo Gerardo Legorreta
Sector: Healthcare
Employees: 75
Address: 110 East 59th Street, New York, NY 10022
Phone: 212 883 0200
Last updated: 2024-12-31
Pfizer Inc.
biopharmaceutical products
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide, offering medicines and vaccines across various therapeutic areas.
About | About | About | About | About | About | About | About | About | About | DEI | ESG | About | Safety | About | ESG | About | About | About | About | About | About | About | About | About | About | History | About | About | About | About | About | About | News | About | Directors | Contact | Careers | Careers | Careers | Careers | Careers | Careers | DEI | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | About | About | About | About | About
Symbol: PFE
Recent Price: $26.42
Industry: Drug Manufacturers - General
CEO: Dr. Albert Bourla D.V.M., Ph.D.
Sector: Healthcare
Employees: 88000
Address: 235 East 42nd Street, New York, NY 10017
Phone: 212 733 2323
Last updated: 2024-12-31
89bio, Inc.
pegozafermin
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for liver and cardio-metabolic diseases, primarily through its lead product candidate, pegozafermin, designed to treat nonalcoholic steatohepatitis and severe hypertriglyceridemia.
Symbol: ETNB
Recent Price: $7.87
Industry: Biotechnology
CEO: Mr. Rohan Palekar
Sector: Healthcare
Employees: 70
Address: 142 Sansome Street, San Francisco, CA 94104
Phone: 415 432 9270
Last updated: 2024-12-31
Ensysce Biosciences, Inc.
PF614, PF614-MPAR, PF329
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company focused on developing prescription drugs for severe pain relief and opioid overdose protection using proprietary abuse-resistant technologies.
Symbol: ENSC
Recent Price: $8.62
Industry: Biotechnology
CEO: Dr. D. Lynn Kirkpatrick Ph.D.
Sector: Healthcare
Employees: 7
Address: 7946 Ivanhoe Avenue, La Jolla, CA 92037
Phone: 858 263 4196
Last updated: 2024-12-31
Erasca, Inc.
ERAS-007, ERAS-601, ERAS-801
Erasca, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.
News | About | About | Careers | Careers | About | Careers | About | About | About | About | About
Symbol: ERAS
Recent Price: $2.55
Industry: Biotechnology
CEO: Dr. Jonathan E. Lim M.D.
Sector: Healthcare
Employees: 126
Address: 10835 Road to the Cure, San Diego, CA 92121
Phone: 858 465 6511
Last updated: 2024-12-31
Lumos Pharma, Inc.
LUM-201
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for rare diseases, with its lead candidate LUM-201 in a Phase 2 trial for pediatric growth hormone deficiency.
Symbol: LUMO
Recent Price: $4.34
Industry: Biotechnology
CEO: Mr. Richard J. Hawkins
Sector: Healthcare
Employees: 33
Address: 4200 Marathon Boulevard, Austin, TX 78756
Phone: 512 215 2630
Last updated: 2024-12-31
Palisade Bio, Inc.
LB1148
Palisade Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing oral therapies targeting serious diseases related to the breakdown of the gastrointestinal mucosal barrier. Their lead product, LB1148, is designed to protect gut integrity during intestinal stress.
Symbol: PALI
Recent Price: $1.70
Industry: Biotechnology
CEO: Mr. J. D. Finley
Sector: Healthcare
Employees: 9
Address: 5800 Armada Drive, Carlsbad, CA 92008
Phone: 858 704 4900
Last updated: 2024-12-31
PDS Biotechnology Corporation
PDS0101
PDS Biotechnology Corporation is a clinical-stage biopharmaceutical company focused on developing multifunctional cancer immunotherapies. Its lead product candidate, PDS0101, is in Phase II clinical trial for treating various human papillomavirus-associated malignancies.
Symbol: PDSB
Recent Price: $1.69
Industry: Biotechnology
CEO: Dr. Frank K. Bedu-Addo Ph.D.
Sector: Healthcare
Employees: 25
Address: 25B Vreeland Road, Florham Park, NJ 07932
Phone: 800 208 3343
Leadership
- Frank Bedu-Addo, Ph.D., Chief Executive Officer, Director
- Stephan Toutain, Chief Operating Officer
- Lars Boesgaard, Chief Financial Officer
- Gregory Conn, Ph.D., Chief Scientific Officer
- Kirk Shepard, M.D., Chief Medical Officer
- Spencer Brown, Senior Vice-President, General Counsel, Corporate Secretary and Compliance Officer
- Rory Cullinane, Vice President of Quality
- Joe Dervan, Ph.D., Vice President of Research and Development
- David Schaaf, M.D., Vice President of Medical Affairs
- Sir Richard Sykes, Director
- Ilian Iliev, Ph.D., Director
- Gregory Freitag, J.D., CPA, Director
- Otis W. Brawley, M.D., Director
- Kamil Ali-Jackson, J.D., Director
- Stephen Glover, Chairman
Last updated: 2024-12-31
Pieris Pharmaceuticals, Inc.
Anticalin-based drugs
Pieris Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company focused on discovering and developing anticalin-based drugs for respiratory diseases, idiopathic pulmonary fibrosis, and cancer.
Symbol: PIRS
Recent Price: $13.60
Industry: Biotechnology
CEO: Mr. Stephen S. Yoder J.D.
Sector: Healthcare
Employees: 46
Address: 255 State Street, Boston, MA 02109
Phone: 857 246 8998
Last updated: 2024-12-31
Poseida Therapeutics, Inc.
P-PSMA-101
Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company focusing on developing innovative CAR-T therapies for patients with high unmet medical needs, including treatments for prostate cancer, multiple myeloma, and various solid tumors.
Symbol: PSTX
Recent Price: $9.48
Industry: Biotechnology
CEO: Dr. Kristin Yarema Ph.D.
Sector: Healthcare
Employees: 337
Address: 9390 Towne Centre Drive, San Diego, CA 92121
Phone: 858 779 3100
Last updated: 2024-12-31
Regulus Therapeutics Inc.
RG-012 and RGLS8429
Regulus Therapeutics Inc., based in San Diego, focuses on discovering and developing drugs targeting micro RNAs for treating various diseases.
Symbol: RGLS
Recent Price: $1.50
Industry: Biotechnology
CEO: Mr. Joseph P. Hagan M.B.A.
Sector: Healthcare
Employees: 30
Address: 4224 Campus Point Court, San Diego, CA 92121
Phone: 858 202 6300
Last updated: 2024-12-31
scPharmaceuticals Inc.
FUROSCIX
sc Pharmaceuticals Inc. is a pharmaceutical company focused on developing and commercializing pharmaceutical products, with a lead product candidate, FUROSCIX, aimed at treating congestion in heart failure patients using an on-body infusor.
About | Leadership | Contact | Contact | Careers | About | About | About | About | Careers | Careers | Careers | Careers | About | About | About
Symbol: SCPH
Recent Price: $3.50
Industry: Biotechnology
CEO: Mr. John H. Tucker
Sector: Healthcare
Employees: 135
Address: 2400 District Avenue, Burlington, MA 01803
Phone: 617 517 0730
Leadership
- John H. Tucker, President and Chief Executive Officer
- Rachael Nokes, Chief Financial Officer
- Mike Hassman, Senior Vice President, Technical Operations
- John Mohr, Pharm.D., FIDP, Senior Vice President, Clinical Development and Medical Affairs
- William T. Abraham, MD,
- Mette Kirstine Agger, Co-Founder & CEO, 7TM Pharma A/S
- Minnie V. Baylor-Henry, President, B-Henry & Associates
- Sara Bonstein, CFO, Insmed Incorporated
- Frederick Hudson, Former Partner in Charge of KPMG’s Largest Healthcare Industry Audit Practice Located in the Mid-Atlantic Region
- Jack A. Khattar, Founder, President & Chief Executive Officer, Supernus Pharmaceuticals
- Leonard D. Schaeffer, Founding Chairman & CEO, Wellpoint
- Klaus Veitinger, MD, PhD, Venture Partner, Orbimed
- Dan Bensimhon, MD, Medical Director Advanced Heart Failure & Mechanical Circulatory Support Program, Cone Health, Greensboro, NC
- G. Michael Felker, MD, Chief, Heart Failure Service, Division of Cardiology, Duke University School of Medicine
- Marv Konstam, MD, Professor of Medicine, Tufts University School of Medicine, Chief Physician Executive of the Cardiovascular Center at Tufts Medical Center
- W. Frank Peacock, MD, FACEP, FACC, FESC, Professor, Vice Chair of Research, Department of Emergency Medicine, Baylor College of Medicine, Ben Taub General Hospital
- Stuart Russell, MD, Regional Director of Heart Failure Program, Duke University School of Medicine
- James E. Udelson, MD, Chief, Division of Cardiology, Tufts Medical Center, Professor of Medicine and Radiology Tufts University School of Medicine
- William Weintraub, MD, Director of Outcomes Research, MedStar Heart and Vascular Institute
Last updated: 2024-12-31
Galecto, Inc.
GB2064
Galecto, Inc. is a clinical-stage biotechnology company focused on developing molecules for the treatment of fibrosis, cancer, inflammation, and related diseases. Their lead product candidate, GB2064, is in Phase IIa for myelofibrosis. The company also advances other candidates targeting severe fibrotic lung diseases and cancer.
Symbol: GLTO
Recent Price: $4.60
Industry: Biotechnology
CEO: Dr. Hans T. Schambye M.D., Ph.D.
Sector: Healthcare
Employees: 13
Address: 75 State Street, Boston, MA 02109
Phone: 457 070 5210
Last updated: 2024-12-31
Nuvectis Pharma, Inc.
NXP800, NXP900
Nuvectis Pharma, Inc., is a biopharmaceutical company that focuses on developing precision medicines for treating serious unmet medical needs in oncology. It is working on products like NXP800, a heat shock factor 1 pathway inhibitor, and NXP900, a drug candidate targeting Proto-oncogene c-Src and YES1 kinases.
Symbol: NVCT
Recent Price: $5.14
Industry: Biotechnology
CEO: Mr. Ron Bentsur M.B.A.
Sector: Healthcare
Employees: 13
Address: 1 Bridge Plaza, Fort Lee, NJ 07024
Phone: 201 614 3150
Last updated: 2024-12-31
Praxis Precision Medicines, Inc.
PRAX-114, PRAX-944, PRAX-562, PRAX-222, KCNT1 program
Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders characterized by neuronal imbalance, with multiple products in different stages of clinical trials.
Symbol: PRAX
Recent Price: $76.26
Industry: Biotechnology
CEO: Mr. Marcio Silva De'Souza M.B.A.
Sector: Healthcare
Employees: 82
Address: 99 High Street, Boston, MA 02110
Phone: 617 300 8460
Last updated: 2024-12-31
PaxMedica, Inc. Common Stock
PAX-101
Pax Medica, Inc., is a clinical stage biopharmaceutical company focused on developing anti-purinergic drug therapies for treating intractable neurologic disorders. Their lead product, PAX-101, is an intravenous formulation of suramin for indications such as autism spectrum disorder and chronic fatigue syndrome.
Symbol: PXMD
Recent Price: $0.06
Industry: Biotechnology
CEO: Mr. Howard J. Weisman
Sector: Healthcare
Employees: 6
Address: 303 South Broadway, Tarrytown, NY 10591
Phone: 914-987-2876
Last updated: 2024-12-31